Sight Sciences/$SGHT
1D1W1MYTD1Y5YMAX
Capital at risk
About Sight Sciences
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
- Ticker
- $SGHT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 186
- Headquarters
- Menlo Park, United States
- Website
- www.sightsciences.com
Sight Sciences Metrics
BasicAdvanced
$511M
-
-$0.56
2.42
-
Price and volume
Market cap
$511M
Beta
2.42
52-week high
$9.34
52-week low
$3.19
Average daily volume
224K
Financial strength
Current ratio
4.949
Quick ratio
4.446
Long term debt to equity
0.595
Total debt to equity
0.794
Interest coverage (TTM)
-3.82%
Profitability
EBITDA (TTM)
-19.264
Gross margin (TTM)
87.96%
Net profit margin (TTM)
-35.69%
Operating margin (TTM)
-23.60%
Effective tax rate (TTM)
0.10%
Revenue per employee (TTM)
$450,000
Management effectiveness
Return on assets (TTM)
-10.84%
Return on equity (TTM)
-48.42%
Valuation
Price to revenue (TTM)
5.946
Price to book
9.59
Price to tangible book (TTM)
9.59
Price to free cash flow (TTM)
-21.25
Free cash flow yield (TTM)
-4.71%
Free cash flow per share (TTM)
-0.436
Growth
Revenue change (TTM)
9.27%
Earnings per share change (TTM)
-42.02%
3-year revenue growth (CAGR)
0.76%
3-year earnings per share growth (CAGR)
-27.67%
What the Analysts think about Sight Sciences
Analyst ratings (Buy, Hold, Sell) for Sight Sciences stock.
Analyst projections of the future price of Sight Sciences stock.
Bulls say / Bears say
Second-quarter revenue rose 20% year on year, with growth in both glaucoma and dry eye. Sight Sciences raised its 2026 revenue guidance to $88m-$92m, implying 14%-19% growth. (BioSpace)
Payer access is improving: Aetna added OMNI and SION to its covered glaucoma procedures for about 25 million commercial lives. The FDA also expanded TearCare’s indication to include improving meibomian gland function, strengthening its clinical and commercial positioning. (Sight Sciences, Sight Sciences)
The company is showing operating leverage as sales recover. Second-quarter operating expenses fell 11% year on year, while management reduced its 2026 adjusted operating expense guidance to $92m-$94m. (BioSpace)
Sight Sciences remains loss-making and cash-consuming. It reported a $17.4m net loss for the first half, held $79.8m of cash against $40m of debt, and says additional financing could be needed if revenue and cost improvements fall short. (StockTitan)
TearCare’s reimbursement opportunity is still incomplete. Management said roughly 70% of dry-eye patients are covered by commercial plans, yet its current focus is mainly on Medicare markets with established fee schedules while it continues seeking broader commercial coverage. (StockAnalysis)
The Alcon patent case may not provide near-term cash. Although Sight Sciences has a $55.4m damages judgment and a 10% ongoing royalty award, Alcon has appealed, related patent re-examinations remain pending, and the company said no cash had yet been received. (StockTitan)
Data summarised monthly by Lightyear AI. Last updated on 28 Sept 2026.
Sight Sciences Financial Performance
Revenues and expenses
Sight Sciences Earnings Performance
Company profitability
Upcoming events
No upcoming events
Sight Sciences News
AllArticlesVideos
Funds containing Sight Sciences
Fund name | Fund size | $SGHT weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.